LONA
What one share of LeonaBio holds
Biological Products, (No Diagnostic Substances)
We are a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (“ALS”), with the goal of improving patients’ lives.
LeonaBio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$10.88 |
|---|---|
| Cash and investments | $3.43 |
| Book value | $3.57 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$14.47 | — | −$10.41 | — | −$54.16 |
| 2020 | — | −$16.68 | $1.94 | −$22.09 | — | — |
| 2021 | — | −$14.86 | $0.43 | −$12.10 | — | $85.90 |
| 2022 | — | −$25.35 | $0.30 | −$19.51 | — | $62.08 |
| 2023 | — | −$30.95 | $0.08 | −$26.58 | — | $34.11 |
| 2024 | — | −$25.19 | $0.01 | −$25.26 | — | $11.49 |
| 2025 | — | −$24.70 | — | −$10.69 | — | $2.98 |